Empirical Finance LLC Buys 364 Shares of DexCom, Inc. (NASDAQ:DXCM)

Empirical Finance LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,619 shares of the medical device company’s stock after acquiring an additional 364 shares during the quarter. Empirical Finance LLC’s holdings in DexCom were worth $846,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Legal & General Group Plc grew its position in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the period. 1832 Asset Management L.P. grew its holdings in DexCom by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after buying an additional 20,400 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its position in DexCom by 14.4% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock worth $183,336,000 after buying an additional 203,043 shares during the period. Finally, Rathbones Group PLC lifted its holdings in shares of DexCom by 5.8% during the second quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock worth $158,936,000 after buying an additional 76,727 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 1.6 %

DXCM opened at $75.88 on Friday. The company has a market cap of $29.64 billion, a P/E ratio of 45.44, a PEG ratio of 2.22 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company’s 50 day moving average is $70.03 and its 200-day moving average is $91.67. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DXCM shares. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. BTIG Research reduced their price target on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. JPMorgan Chase & Co. lifted their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Morgan Stanley reduced their target price on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.